[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kenakin, 2002 - Google Patents

Drug efficacy at G protein–coupled receptors

Kenakin, 2002

View PDF
Document ID
971509883877280457
Author
Kenakin T
Publication year
Publication venue
Annual review of pharmacology and toxicology

External Links

Snippet

Efficacy has been defined in receptor pharmacology as a proportionality factor denoting the amount of physiological response a given ligand imparts to a biological system for a given amount of receptor occupancy. While first defined in terms of response, the concept can be …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/566Immunoassay; Biospecific binding assay using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones

Similar Documents

Publication Publication Date Title
Kenakin Drug efficacy at G protein–coupled receptors
Kenakin Biased receptor signaling in drug discovery
Ballante et al. Structure-based virtual screening for ligands of G protein–coupled receptors: what can molecular docking do for you?
Jacoby et al. The 7 TM G‐protein‐coupled receptor target family
Surgand et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors
Scheer et al. Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the α1b-adrenergic receptor: effects on receptor isomerization and activation
Fanelli et al. Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis
Oliveira et al. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure
Katada et al. Structural basis for a broad but selective ligand spectrum of a mouse olfactory receptor: mapping the odorant-binding site
Flower Modelling G-protein-coupled receptors for drug design
Vauquelin et al. G protein‐coupled receptors: a count of 1001 conformations
Galandrin et al. The evasive nature of drug efficacy: implications for drug discovery
Luttrell Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery
Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
Gudermann et al. Functional and structural complexity of signal transduction via G-protein-coupled receptors
Scheer et al. Minireview: constitutively active G protein-coupled receptors: potential mechanisms of receptor activation
McAllister et al. A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition
US20020061599A1 (en) Method of identifying ligands of biological target molecules
Yoshikawa et al. Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands
López-Rodrı́guez et al. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine1a receptor ligands to explore the three-dimensional structure of the receptor
Nicoli et al. Classification model for the second extracellular loop of class A GPCRs
Umanah et al. Changes in conformation at the cytoplasmic ends of the fifth and sixth transmembrane helices of a yeast G protein-coupled receptor in response to ligand binding
Cawston et al. Molecular basis for binding and subtype selectivity of 1, 4-benzodiazepine antagonist ligands of the cholecystokinin receptor
Huang et al. Dynamics and mechanistic underpinnings to pharmacology of class A GPCRs: an NMR perspective
Yuzlenko et al. Molecular modeling of A1 and A2A adenosine receptors: Comparison of rhodopsin‐and β2‐adrenergic‐based homology models through the docking studies